Grünenthal USA, Inc.

360 Mount Kemble Avenue

Morristown, NJ 07960

Phone:  908-306-0024

Fax:  908-306-1631


Grünenthal USA Inc.

Grünenthal USA is a subsidiary of Grünenthal GmbH, an independent, family-owned pharmaceutical company specializing in pain management. Grünenthal USA partners with other leading pharmaceutical companies to deliver innovative products to patients living with pain.

As an independent, family-owned company, we at Grünenthal treat pain using a family approach. We realize that when a loved one is sick, the entire family is affected. Often times the patient is so consumed with pain that it is impossible to focus on the best possible choices for pain relief and other care services. It is the family members that step in and provide necessary support by gathering information and discussing the best approach for relief. At Grünenthal, we are passionate about being the preferred partner in pain management worldwide, thereby contributing to patients and families' peace of mind and quality of life.

Family businesses have often been described as unique business entities. In such environments, employees are treated as an extension of the family and their input and creativity is valued and appreciated. At Grünenthal USA the collective sum of input and experiences from our employees drive innovativeness and find solutions to patients living with pain.

The Grünenthal Group: International, successful, innovative

The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. We are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value-adding products to markets.Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients.

Grünenthal is one of five remaining research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. Research and development costs amounted to about 19 percent of revenues in 2016. Grünenthal's research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies.

Altogether, the Grünenthal Group is present in 32 countries with affiliates in Europe, Latin America and the US. Grünenthal products are sold in more than 155 countries and currently approx. 5,500 employees are working for the Grünenthal Group worldwide. In 2016, Grünenthal achieved revenues of € 1.4 bn.